NEW YORK (GenomeWeb News) – Newly formed Selah Genomics today announced that it has acquired EnGenCore for an undisclosed amount.

Selah CEO Michael Bolick said in a statement that the purchase of EnGenCore will lead to the development of "molecular and genomic technology at [the University of South Carolina] with an eye toward helping translate this impactful technology to the clinic." The firm's Clinical Genomics Center is located at the GHS Institute for Translational Oncology Research in close proximity to the USC medical school, he noted.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.